Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients completed the core study BAF312A2201~* Written informed consent provided before any assessment of the extension study~* Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception~Exclusion Criteria:~* Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)~* Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions~* Active infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 56 Years
- Healthy Volunteers: f

Study Arms:
- BAF312 10 mg/2 mg (Type: EXPERIMENTAL): 10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 2 mg/2 mg (Type: EXPERIMENTAL): 2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 1.25 mg/2 mg (Type: EXPERIMENTAL): 1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 .5 mg/2 mg (Type: EXPERIMENTAL): .5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 .25 mg/2 mg (Type: EXPERIMENTAL): .25 mg dose in Double Blind Phase and 2 mg in Open Label Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).